The drug, a partial dopamine agonist, has been studied in approximately 2650 patients with schizophrenia at more than 200 phase 2 and 3 clinical trial sites, the release concludes.

• 此药属于部分多巴胺致效剂，在超过200个第2和第3期试验中，有将近2,650位精神分裂病患参与。